anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
While microplastics have been recently detected in human blood and the placenta, their impact on human health is not well understood. Using a mouse model of environmental exposure during pregnancy, our group has previously reported that exposure to polystyrene micro- and nanoplastics throughout gestation results in fetal growth restriction. While polystyrene is environmentally relevant, polyethylene is the most widely produced plastic and amongst the most commonly detected microplastic in drinking water and human blood. In this study, we investigated the effect of maternal exposure to polyethylene micro- and nanoplastics on fetal growth and placental function. Healthy, pregnant CD-1 dams were divided into three groups: 106 ng/L of 740-4990 nm polyethylene with surfactant in drinking water (n = 12), surfactant alone in drinking water (n = 12) or regular filtered drinking water (n = 11). At embryonic day 17.5, high-frequency ultrasound was used to investigate the placental and fetal hemodynamic responses following exposure. While maternal exposure to polyethylene did not impact fetal growth, there was a significant effect on placental function with a 43% increase in umbilical artery blood flow in the polyethylene group compared to controls (p < 0.01). These results suggest polyethylene has the potential to cause adverse pregnancy outcomes through abnormal placental function.
Oral Tapentadol 100 mg to 250 mg twice daily. Tablet taken orally, twice daily, morning \& evening with preferably 12 hours (not less than 6 hours) between doses.
After being informed about the study and potential risks, all patients giving written informed consent will undergo screening serology and preoperative work-up to determine eligibility for study entery. Patients who meet the eligibility requirements will be treated for their fistulas by combined minor surgical debridement of the fistula tract and closure of the internal orifice as well as liposuction from the abdominal wall. Regenerative cells- enriched lipoaspirate will be injected around the entire length of the fistula tract. The first five patients will receive their own regenerative cells and act as donors for the next included patients, but they will not be included in the final analysis. The rest of the included patients (70) will be randomized in double-blinded manner (participant and investigator) in a 1:1 ratio to either recieve own regenerative cells (ADRC Adipose-Derived Regeneative Cells) or donated cultured regenerative cells (ADRC001). All included patients will be scheduled for follow-up at 3, 6 and 12 months after treatment.
INTRODUCTION: In many postmenopausal women, quality of life is decreased due to vasomotor symptoms. Efficient and well-tolerated non-hormonal treatment options are needed.
AREAS COVERED: The present review summarizes what is known about the etiology of postmenopausal vasomotor symptoms as a rationale for the mechanism of action of Elinzanetant, a new neurokinin (NK)-1/-3 receptor antagonist, as well as its efficacy and side effect profile.
EXPERT OPINION: Elinzanetant likely exerts an antagonistic effect on the NK-3 receptor in the preoptic thermoregulatory zone, but also an additional antagonistic effect on the NK-1 receptor possibly leading to a reduction in vasodilatation and heat-sensing neuro-activity. Elinzanetant's reported peak drug concentrations are reached within one hour and the terminal elimination half-life is approximately 15 hours. Two phase IIb clinical trials evaluated the safety profile and efficacy of several doses. There were no serious adverse events, which also included a lack of evidence of drug-related hepatotoxicity. Overall, Elinzanetant seems to be well-tolerated. In the SWITCH-1 study, the 120 mg/day and 160 mg/day regimen showed good efficacy for the treatment of vasomotor symptoms and led to significant improvements in quality of life. Thus, 120 mg oral Elinzanetant/day was used in phase III trials, whose results have not yet been published.
Participants will receive Fumaderm initial/Fumaderm tablets by self administration at week 0. The individual FAE dose representing the optimal efficacy/tolerability ratio needs to be determined for each participant according to local prescription information. To this aim, FAE doses will be slowly increased beginning with increasing doses of Fumderm initial (containing 30 mg dimethylfumarate) over the first 3 weeks. Thereafter, participants will be switched to Fumaderm tablets (containing 120 mg dimethylfumarate) starting with 1 tablet per day. Fumaderm dose may be increased to a maximum of 3\*2 tablets per day. The decision to maintain, increase or decrease the FAE dose depends on efficacy, safety and tolerability.
Chronic lymphocytic leukemia (CLL) is an incurable indolent non-Hodgkin lymphoma characterized by tumor B cells that weakly express a B-cell receptor. The mutational status of the variable region (IGHV) within the immunoglobulin heavy chain (IGH) locus is an important prognosis indicator and raises the question of the CLL cell of origin. Mutated IGHV gene CLL are genetically imprinted by activation-induced cytidine deaminase (AID). AID is also required for IGH rearrangements: class switch recombination and recombination between switch Mu (Sμ) and the 3' regulatory region (3'RR) (Sμ-3'RRrec). The great majority of CLL B cells being unswitched led us to examine IGH rearrangement blockade in CLL. Our results separated CLL into two groups on the basis of Sμ-3'RRrec counts per sample: Sμ-3'RRrecHigh cases (mostly unmutated CLL) and Sμ-3'RRrecLow cases (mostly mutated CLL), but not based on the class switch recombination junction counts. Sμ-3'RRrec appeared to be ongoing in Sμ-3'RRrecHigh CLL cells and comparison of Sμ-3'RRrec junction structural features pointed to different B-cell origins for both groups. In accordance with IGHV mutational status and PIM1 mutation rate, Sμ-3'RRrecHigh CLL harbor a non-germinal center experienced B-cell imprint while Sμ-3'RRrecLow CLL are from AID-experienced B cells from a secondary lymphoid organ. In addition to the proposals already made concerning the CLL cell of origin, our study highlights that analysis of IGH recombinatory activity can identify CLL cases from different origins. Finally, on-going Sμ-3'RRrec in Sμ-3'RRrecHigh cells appeared to presumably be the consequence of high c-MYC expression, as c-MYC overexpression potentiated IGH rearrangements and Sμ-3'RRrec, even in the absence of AID for the latter.
Hepatocellular carcinoma (HCC) continues to be the most prevalent type of liver cancer worldwide. Diethylnitrosamine (DEN)-induced HCC is an extensively used hepatic cancer model in experimental animals. Acetazolamide (AZA) is a carbonic anhydrase enzyme inhibitor. This study aimed to assess the therapeutic mechanism of AZA against DEN-induced HCC. Thirty male Wistar albino rats were divided equally into three groups. Group I (C): control group, Group II (HCC): DEN-induced HCC, and Group III (HCC/AZA): AZA-treated HCC. Verification of the HCC induced by DEN was confirmed by elevated liver enzymes' activities, and increased α-fetoprotein (AFP) levels, as well as distinct liver architecture changes. On the other hand, the AZA-treated HCC group experienced decreases in the activities of serum liver enzymes and AFP levels, as well as, regulated liver architecture. Additionally, it downregulated p-p38 MAPK/p-JNK1/JNK2/p-C-Jun/p-NF-κB p65 protein expressions. Moreover, it ameliorated autophagy by controlling the expression of the p-AMPK/p-mTOR1/LC3 I/II proteins. Furthermore, it downregulated the relative gene expressions of carbonic anhydrase-IX (CAIX) and hexokinase-II (HKII). Histopathological examination of AZA-treated HCC liver tissues supported these findings. Conclusion: AZA provides a new dimension in ameliorating experimentally induced HCC through regulation of hepatic biomarkers, antioxidant status, inflammatory markers, and autophagy, mediated by amelioration of CAIX and HKII gene expressions.
Samples and controls are sorted and re-sorted for CD34, CD38, and CD55 subsets by single-cell PCR analysis, flow cytometry, and reverse-transcriptase PCR. Sorted cell subsets are then transplanted into NSG mice. Beginning 6 weeks after transplantation, peripheral blood samples are collected and analyzed for human lymphoid- and myeloid-lineage cells by FACS.
The physical therapist will read a script indicating that the intervention may or may not be an effective treatment for knee osteoarthritis and may nor may not reduce pain and improve strength. Patients are then instructed on the home exercise program and how to operate the TENS unit. The duration of intervention is 1 week during which patients will wear then wear the TENS unit for 8 hours per day and perform no more than 3 sets of 10 repetitions of the physical therapy exercises daily.
In an implementation, processing blockchain-based data is described. Data to be stored in a blockchain network is received at one or more processing devices of a blockchain node. A determination is made that an attribute of the data is of a particular type. In response to determining that the attribute of the data is of the particular type, a digest representing the data is generated. The digest is smaller in size than the data. The data is stored at a storage location in accordance with a mapping relationship between the digest and a first identifier of the data. An encrypted version of the digest is generated, by the one or more processing devices for storage on the blockchain network, using a private key of a public-private key pair corresponding to a second identifier of the data.
In some aspects, methods of inhibiting survival or proliferation of a tumor cell are provided, the methods comprising inhibiting the glycine cleavage system (GCS) of the tumor cell. In some aspects, methods of treating a subject in need of treatment for a tumor, the method comprising inhibiting the GCS in the tumor. In some embodiments, the methods comprise contacting a tumor cell or tumor with a GCS inhibitor. In some embodiments, the tumor cell or tumor has elevated expression of serine hydroxymethyltransferase 2 (SH1VIT2). In some aspects, methods of identifying a tumor cell or tumor that is sensitive to inhibiting the GCS are provided, the methods comprising determining whether the tumor cell or tumor overexpresses SHMT2. In some aspects, methods of identifying a candidate anti-cancer agent are provided, the methods comprising identifying or modifying a GCS inhibitor.
PURPOSE:A base composition consisting of a compound selected from a specific chain polydimethylsiloxane and a specific cyclic polydimethylsiloxane and a lower alcohol, and capable of enhancing the percutaneous absorbability of a chemical. CONSTITUTION:A base composition, containing at least one compound selected from a chain polydimethylsiloxane having <=3 cSt viscosity at 25 deg.C, e.g. a compound of the formula (n is an integer 0-6) and a cyclic polydimethylsiloxane having <=5 cSt viscosity at 25 deg.C, e.g. cyclooctamethyltetrasiloxane, and a lower alcohol, e.g. methyl alcohol or ethyl alcohol, and capable of enhancing the percutaneous absorbability of a chemical. The amount of the compound is 1- 50wt% based on the lower alcohol. A chemical having 0.5-5% solubility in the lower alcohol is capable of enhancing the percutaneous absorbability by the above-mentioned composition.
The present invention relates to peptides being the N-terminal fragment of human proinsulin C-peptide and having the sequence EAEDLQVGQVEL (SEQ ID No: 2) or a fragment or peptide derivative thereof retaining the functional ability of the N-terminal fragment to contribute to C-peptide activity, wherein said fragment or peptide derivative comprises two acidic amino acid residues and is capable of adopting a conformation where said two acidic amino acid residues are spatially separated from one another by a distance of 9-14 Å between the α-carbons thereof; and wherein said peptide derivative does not include native C-peptide of any species nor human C-peptide 1-15, 1-24 or 1-26 or rat C-peptide 1-26. The invention also relates to peptides having an amino acid sequence comprising (i) the N-terminal fragment of human insulin C-peptide having the sequence EAEDLQVGQVEL (SEQ ID NO. 2) or (ii) a fragment or peptide derivative of amino acid sequence SEQ ID NO. 2 retaining the functional ability of said N-terminal fragment to contribute to C-peptide activity, wherein said fragment or peptide derivative comprises two acidic amino acid residues and is capable of adopting a conformation wherein said two acidic amino acid residues are spatially separated from one another by a distance of 9-14 Å between the a-α-carbons thereof; said peptide having C-peptide activity, but not including native C-peptide of any species nor human C-peptide 1-15, 1-24 or des 13-17. The invention further relates to peptides having the formula Xn-Y-Xm-Y-Xp where X is any amino acid, Y is an acidic amino acid, n=0-6, m=5-9 and p=0-6. First and second medical indications, pharmaceutical compositions and products for use as a combined preparation are also covered by the present invention.
IRD presents a significant burden on the NHS as well as on the individual and families. IRDs are particularly difficult in a family situation due to guilt and other complex emotions related to inheritance patterns. Poorer mental health has been reported in patients with retinitis pigmentosa, manifesting in a range of ways including stress, depression and anxiety, particularly as the disease progresses. This is most probably caused by the uncertainty of the disease process and the progressive nature of the degeneration.

Recent work has reported that quality of life significantly deteriorates with a drop in visual field diameter of 20 degrees or a drop in visual acuity lower then LogMAR 0.3 (equivalent to 6/12). Contrast sensitivity is often used in conjunction with VA to assess visual capabilities. It is a measure of the ability to see reduced contrast and has a major impact on utility of vision. Relating contrast sensitivity function to quality of life will provide valuable information about whether this aspect of vision is a critical measure for patient health. This is especially important as novel treatments are being developed for the treatment of IRDs.
The present invention relates to a technological process for purifying bee glue, which is realized by the method that a dissolvant ethanol solution is directly used for extracting course bee glue, and then, the technological steps of still standing, filtering, distilling for recovering ethyl alcohol, drying by hot air, cooling, grinding, etc. are carried out. Compared with the prior art, the present invention has the advantages of simple process, practicality and low cost. The wax content and other indexes of the bee glue prepared by the process of the present invention conform to the standard of that of natural bee glue. The thermal stability of the bee glue is good, and the bee glue can not be condensed at normal temperature. Thus, the bee glue can be milled without adding anticoagulation agents, and prepared bee glue powder is convenient for further use.
We will recruit participants with sarcopenia or possible sarcopenia. The participants will be divided into 2 groups. One group, the "integrated care" group, will receive both the peripheral functional magnetic stimulation to both the upper and lower limbs and nutritional supplement for consecutive 8 weeks. The other group, the "usual care" group, will receive an educational digital versatile disc (DVD) and a handbook for exercise suggestions on sarcopenia. We will compare before and after the intervention about the body composition, handgrip strength, 5-time chair stand test, 6-meter walk, and blood test for C-reactive protein and other cytokines related to sarcopenia. The participant's nutritional condition, activity level, life quality will also be analyzed via questionnaires before and after the intervention.
Group 3: Combined (Combined points/tickets): Participants in group 3 will be able to earn 5 points and one lottery ticket for 10 minutes of walking. The daily lottery in this condition will be for 500 BetterPoints (rather than 1000 BetterPoints in group 2) and therefore each ticket will have an expected value (EV) of 5 BetterPoints. Participants will be able to earn points and tickets in this way for up to 40 minutes of walking per day.
Subjects will be weaned from CPAP (when FiO2 \<0.30) to Nasal cannula (2 L/min) with whatever FiO2 they need until they are off oxygen and NC completely. However, if these infants fail on NC they will be put back to nCPAP. Infants will then be maintained on CPAP until stable on CPAP-30% for 24 hours. Infants will be tried for another weaning using NC. So, infants assigned to NC will be weaned only through NC. CPAP will be used only for stabilization in between trials if needed.
Participants will consume a personalized meal plan for 2 weeks and consume an increased quantity of fish to 6 oz. wild salmon (1 steak, 6oz /steak)or 14.3 oz. (5.5 packs, 2.6 oz/pack) of chunk light tuna (1020 mg Omega-3LC/week) for 6 weeks.
Many lower-socioeconomic status (SES) children live in crowded homes and lack their own bed, which can contribute to insufficient and poor quality sleep and related poor child and family functioning. The Beds for Kids program provides beds and bedding to disadvantaged children in Philadelphia, and has been found to positively impact parent-reported child sleep in a previous pilot study. However, there is a need to determine the impact of the Beds for Kids program on objectively assessed child sleep, as well as on daily child behavior and caregiver functioning (mood and sleep). The primary objective of this study is to evaluate the impact of provision of a child bed through the Beds for Kids program on objectively measured child sleep, and on daily child behavioral functioning and caregiver functioning over a 14-day period for preschool-aged children. This is a randomized controlled trial (RCT). Caregiver-child dyads will be assigned to the intervention group, in which they receive a bed through the Beds for Kids program after a 7-day period, or to the waitlist control group, in which they receive a bed after a 14-day period. The primary study outcome is the difference between study conditions in actigraph-derived and caregiver-reported child sleep (bedtime, bedtime variability, sleep quality, night wakings, total sleep duration) for days 7 to 14 (bed vs control), as well as compared to baseline. Thus, this is a mixed between (bed vs waitlist) and within (days 1-7 vs days 8-14) group design.
A chromatographic test strip comprising a solid support having at least a first portion and a second portion with said portions being in the same plane so as to permit capillary flow communication with each other. The sample is added to the first portion. The first portion also may comprise a tracer portion having a tracer movably supported therein. The tracer consists of a visible particulate marker. In the second portion, a binder is immobilized. The test strip is useful in a variety of immunoassays.
<P>PROBLEM TO BE SOLVED: To provide a sheet for skin care which is flexible, excels in the touch (the feel of the skin), and has a high liquid absorptivity, and a wet sheet in which its sheet is impregnated with a liquid compound.  <P>SOLUTION: In the sheet for the skin care which comprises a spunbonded fabric capable of being impregnated with the liquid compound, the spunbonded fabric has an average fineness of 0.5 or less dtex, is formed of a superfine long-fiber comprising a water insoluble thermoplastic resin, and contains a water-soluble thermoplastic resin in the spunbonded fabric at a rate of 0.001-10 weight%. The surface of the spunbonded fabric at 30% or more may be covered with the water-soluble thermoplastic resin. The water-soluble thermoplastic resin, for example, may be water-soluble thermoplastic polyvinylalcohol. The wet sheet, in which the sheet for the skin care is impregnated with the liquid compound, is suitable for a face mask, a makeup removing sheet, and a sheet for cleaning the body, etc.  <P>COPYRIGHT: (C)2007,JPO&INPIT
A system may include a data processor and a memory having instructions stored thereon. The instructions may perform operations when executed by the data processor. The operations may include: determining, based on position data from a positioning system, that a cartridge, which may contain a drug, is present at a certain position. The amount of drug can be determined based on volumetric data from the volumetric meter at the location. The transfer of the drug may be detected based on the presence of the cartridge in said position and/or the amount of drug. Related methods and articles of construction including apparatus and computer program products are also disclosed.
Carcinogenicity studies with enfortumab vedotin-ejfv or the small molecule cytotoxic agent (MMAE) have not been conducted.

MMAE was genotoxic in the rat bone marrow micronucleus study through an aneugenic mechanism. This effect is consistent with the pharmacological effect of MMAE as a microtubule-disrupting agent. MMAE was not mutagenic in the bacterial reverse mutation assay (Ames test) or the L5178Y mouse lymphoma forward mutation assay.

Fertility studies with enfortumab vedotin-ejfv or MMAE have not been conducted. However, results of repeat-dose toxicity studies indicate the potential for enfortumab vedotin-ejfv to impair female and male reproductive function and fertility.

In repeat-dose toxicology studies conducted in rats for up to 13 weeks, doses ≥2 mg/kg enfortumab vedotin-ejfv (at exposures similar to the exposures at the recommended human dose) resulted in decreases in testes and epididymis weights, seminiferous tubule degeneration, spermatid/spermatocyte depletion in the testes and cell debris, sperm granuloma and hypospermia/abnormal spermatids in the epididymis. Findings in the testes and epididymis did not reverse by the end of the recovery period. 

MMAE-containing ADCs have been associated with adverse ovarian effects when administered to sexually immature animals. Adverse effects included decrease in, or absence of, secondary and tertiary ovarian follicles after weekly administration to cynomolgus monkeys in studies of 4-week duration. These effects showed a trend towards recovery 6 weeks after the end of dosing; no changes were observed in primordial follicles.
PURPOSE:A poultice containing hydrous gel obtained by emulsifying and dispersing water in a specific oily continuous phase as a base, and having improved water holding property, adhesive property, shape retaining property, etc. CONSTITUTION:A poultice containing a base obtained by dispersing 1-60wt% water in an oily continuous phase containing 10-60wt% carboxy-modified liquid rubber, e.g. modified rubber obtained by reacting low-molecular weight polyisoprene, etc. with maleic anhydride, etc., and 5-40wt% oil component, e.g. liquid paraffin, etc. with 1-10wt% emulsifying agent, e.g. nonionic surfactant such as polyoxyethylene alkyl ether or metal soap such as magnesium stearylphosphate, and incorporating 0.5-4wt% crosslinking agent, e.g. metal based crosslinking agent such as zinc oxide, amine based crosslinking agent or epoxy based crosslinking agent, and 1-10wt% drug effect component, e.g. analgesic and antiphlogistic agent,anti-inflammatory agent of antihypertensive agent. EFFECT:Easily usable with improved stability and shape retaining property without absorption of water from the outside nor sagging or sticking.
Clinical patients participants will receive serial doses of Rb-82 administered as either a bolus (B) (gold standard) or slow infusion (SI). Under resting conditions, they will receive 3 weight based doses. The first two doses are randomly assigned B and SI. The third dose is either B or SI. Under stress conditions, they will receive 2 weight based doses that are randomly assigned B and SI.